Quit Smoking and Health Care

At present, smoking is considered a chronic addictive disease can cause premature death more than half of those who suffer. It’s called chronic disease for those patients requiring long-term, designed to cure or can not be clearly predicted and will never happen. Any disease that has a duration longer than six months can be regarded as chronic medical terms as they may be multiple causes occur but in the case of smoking is a social disease that affects us all and we are not smokers or our families do not smokers have as costs for diseases related to the consumption of snuff in their high-cost treatments are best known as causing 87% of lung cancers and 93% of cases of chronic obstructive pulmonary disease. It’s an addiction that involves vulnerability to relapse for a long time, which supports its recognition as a chronic disease. Recommendations for clinical treatment of this addiction Different types of intervention, depending on the degree of motivation that the patient has to make a serious quit attempt of snuff consumption.

Since over the past years there have been many studies and meta-analysis that have qualifying what and how to use different types of smoking cessation exist at the present time it is important to know that they are different types of smokers : nonsmokers who never smoked before adulthood, non-smokers who recently left, smokers who do not want to quit smoking and be willing to make a serious quit attempt within these these people who smoke ten or fewer cigarettes in the day. It must do two classes a behavioral intervention, designed to combat suffering psychological dependence and other drug to alleviate physical dependence on nicotine.

Behavioral interventions: This support can range from simple advice to drop more complex behavioral interventions. This type of intervention, when performed by doctors, produces a small but significant increase in abstinence rate minimum intervention provided both by physicians and nurses, both in primary care in hospitals or in hospitals, has been effective and efficient, and its use should be routine clinical practice, all smokers who want to make a serious attempt to quit should receive behavioral support to provide them with sufficient support to be able to overcome psychological dependence, social and gestural that the use of snuff caused. This behavioral support can be offered both individually and in groups. Individual support should be provided in face-to-face with the patient from about 5 to 10 minutes, although the shape and number of these may vary among different groups. It is desirable that such contacts are incidental to another by telephone: the establishment of a series of calls along the quitting phase slightly increased the effectiveness of individual support.

Drug treatment: The recommendation number 2 of the treatment of consumption and dependence snuff public health service in the United States provides that smokers who want to stop the snuff should receive drug treatment whose effectiveness has been demonstrated by meta-analysis performed. First choice, taken because they have proven effective and produce few side effects, and second choice because its efficacy is limited and cause more adverse effects among the first ones, various forms of nicotine replacement therapy (gum, patch, spray and inhaler mouth) and bupropion. Among the latter, clonidine and nortriptyline.

Nicotine replacement therapy: TSN is defined as the administration of nicotine to a smoker who wants to stop being a different route and cigarette consumption in an amount sufficient to alleviate the suffering of withdrawal symptoms, but insufficient to cause dependence gum, patch, spray, oral inhaler, sublingual tablets and lozenges. With all obtained mean values ​​of nicotine that exceed 7 to 10 ng / ml. This figure is considered the minimum necessary to produce a reduction in withdrawal symptoms. Two points to take into account people with this disease first, different studies have shown that women quit smoking less frequently than men, however, analysis of the subpopulation of women in a clinical trial showed that female gender predicted a Index worsening symptoms when smokers were treated with placebo or nicotine patches, but not when receiving bupropion. These data suggest the preferred use of bupropion for the treatment of women smokers, although further studies are needed to support this indication. Two: Gain weight. The abandonment of the use of snuff is followed by weight gain. One study found that the increase may be a cause of recaída49, 62. Moreover, weight gain has been invoked as the cause of more than 40% of recurrences in women smokers who want to remain so.